We at Themison are excited to announce two transformative milestones in our journey: securing a €150K investment from Antler and gaining acceptance into the prestigious Innofounder program with an additional €100K funding. These achievements are a testament to our commitment to revolutionizing patient engagement in clinical trials.

Our collaboration with Antler began in September 2023, catalyzed by our shared vision to tackle the persistent challenge of high dropout rates in clinical trials. This partnership has been crucial in developing our platform, designed to enhance patient retention and accelerate the drug development process through innovative patient-centric approaches.

Being accepted into the Innofounder program, known for its support of startups with high growth potential and societal impact, marks another significant milestone for us. This recognition is not just an endorsement of our innovative approach but also provides us with valuable resources and mentorship to further our development.

Our platform leverages a behavioral algorithm and a customizable app to improve the clinical trial experience, targeting the root causes of patient attrition. This approach aims to streamline trial processes, enhance communication, and offer personalized support to reduce dropout rates significantly.

These milestones—securing funding from Antler and the Innofounder program—reaffirm our mission and strengthen our resolve to make clinical trials more patient-friendly and efficient. As we continue to build our platform and gear up for its first application in a clinical trial, we're more excited than ever about the future.

Together, we are not just envisioning a new era of patient engagement in clinical trials; we are actively building it. Stay tuned for more updates as we move forward on this promising journey, aiming to reshape the landscape of clinical trials for the better.